Resources:
Join us on 10 October for the RWE4Decisions webinar on how RWE over the lifecycle of ATMPs could support the EU joint HTA work. You will hear from Prof Ana Hidalgo-Simon, who will set the scene on the clinical and regulatory context for ATMPs in the EU. A multi-stakeholder panel will then follow, representing the voices of HTA bodies, payers, patients and industry, on the opportunities and challenges with RWE generation and assessment for ATMPs.
Senior Health Economist, Organisation for Economic Co-operation and Development (OECD)
RWE4Decisions Facilitator
Associate Professor, Leiden University Medical Center
Chief Pharmacist, Swedish Dental and Pharmaceuticals Benefits Agency (TLV), RWE4Decisions Steering Group Member
Head of Department Health Policy & Health Economics, Allgemeine Ortskrankenkasse (AoK)
Public Affairs Director, EURORDIS-Rare Diseases Europe, RWE4Decisions Steering Group Member
Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), RWE4Decisions Steering Group Member
Senior Health Economist, Organisation for Economic Co-operation and Development (OECD)
RWE4Decisions Facilitator
Under the EU Health Technology Assessment Regulation (HTAR), oncology medicines and Advanced Therapeutic Medicinal Products (ATMPs) will be the first to undergo Joint Clinical Assessments, starting in January 2025. As there is often a paucity of clinical evidence available for these highly innovative treatments, the 2023 RWE4Decisions webinar series will consider the potential for use of Real-World Data (RWD), given there is no EU-wide guidance on Real-World Evidence (RWE) generation or use.
Public Webinar: From Policy to Practice: EHDS Implementation to Support Better Real-World Evidence for HTA/Payers
RWE4Decisions Symposium: Developing Real-World Evidence to Deliver Innovation in HTA
Public Webinar: HTA/Payer Collaboration in the Nordics: The Role of Real-World Evidence
